Varicella Vaccination in Children

BioDrugs

Volumn 14, Issue 1, 2000, Pages 49-60

  Clements, Dennis A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHICKENPOX VACCINE;

ANTIBODY RESPONSE; CHICKENPOX; CHILD; CHILDHOOD DISEASE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG CONTRAINDICATION; DRUG INDUCED DISEASE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REVIEW; TREATMENT INDICATION; VACCINATION; VARICELLA ZOSTER VIRUS; VIRUS INFECTION;

EID: 0033870017     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200014010-00005     Document Type: Review

References (45)

1. Long-term protective immunity of recipients of the OKA strain of live varicella vaccine
2. A long-term prospective study of varicella vaccine in healthy children
3. Gelatin-specific humoral and cellular immune responses in children with immediate- and nonimmediate-type reactions to live measles, mumps, rubella and varicella vaccines
4. Urticaria following varicella vaccine associated with gelatin allergy
5. Safety of varicella vaccine: Results of post-marketing surveillance in 32,947 recipients of Varivax
6. Safety and immunogenicity of concurrent administration of measles-mumps-rubella-varicella vaccine and Pedvax HIB vaccines in healthy children twelve to eighteen months old
7. Safety and immunogenicity of a combined live attenuated measles, mumps, rubella and varicella vaccine (MMRIIV) in healthy children
8. Evaluation of live attenuated varicella vaccine (Oka-RIT Strain) and combined varicella and MMR vaccination in 13-17 month old children
9. Varicella prevalence in day care centers
10. Varicella sero-prevalence in US populations
11. Prevalence of varicellazoster virus infection in Singapore
12. Population-based studies of varicella complications
13. Varicella: Complications and costs
14. Varicella vaccine: The Japanese experience
15. Postmarketing evaluation of the safety and effectiveness of varicella vaccine
16. Post-licensure study of varicella vaccine effectiveness in a day care setting
17. Varicella-zoster virus vaccine
18. Immunogenicity and safety of a live attenuated varicella vaccine (Oka/SB Bio) in healthy children
19. Live attenuated varicella vaccine: Evidence that the virus is attenuated and the importance of skin lesions in transmission of varicella-zoster virus
20. Transmission of vaccine strain varicella-zoster virus from a healthy adult with vaccine-associated rash to susceptible household contacts
21. Transmission of varicella-vaccine virus from a healthy 12 month-old child to his pregnant mother
22. Live attenuated varicella virus vaccine: Efficacy trial in healthy children
23. Oka/Merck varicella vaccine in healthy children: Final report of a 2 year efficacy study and 7 year follow-up studies
24. Modified cases of chickenpox after varicella vaccination: Correlation of protection with antibody response
25. Efficacy of high-titer live attenuated varicella vaccine in healthy young children
26. Use of a reformulated Oka strain varicella vaccine (SmithKline Beecham Biological/Oka) in healthy children
27. Early results of a trial of the Oka-strain varicella vaccine in children with leukemia or other malignancies in Sweden
28. Live attenuated varicella vaccine use in immunocompromised child and adults
29. Immunization of children with acute lymphoblastic leukemia with live attenuated varicella vaccine without complete suspension of chemotherapy
30. High incidence of breakthrough varicella in healthy Japanese children immunized with live attenuated varicella vaccine (Oka strain)
31. Varicella and zoster in children after kidney transplantation: Long-term results of vaccination
32. Protection against varicella in family contacts by immediate inoculation with live varicella vaccine
33. Childhood vaccination against chickenpox: An analysis of benefits and costs
34. Costs and benefits of routine varicella vaccination in German children
35. The value of varicella vaccination in healthy children: Cost-benefit analysis of the situation in France
36. A cost-benefit analysis of a routine varicella vaccination program for United States Air Force Academy cadets
37. Clinical and economic considerations of vaccinations against varicella
38. Cost-effectiveness of varicella serotesting versus presumptive vaccination of school-age children and adolescents
39. Varicella susceptibility and vaccination strategies in young adults
40. Prevention of chickenpox in reproductive-age women: Cost-effectiveness of routine prenatal screening with postpartum vaccination of susceptibles
41. Cost-effectiveness of the varicella vaccine for administration to health care workers
42. An economic analysis of varicella vaccination for health care workers
43. An economic evaluation of varicella vaccine for pediatric liver and kidney transplant recipients